瀾起科技(688008.SH):2023年員工持股計劃擬募資不超2.5億元
格隆匯4月14日丨瀾起科技(688008.SH)公佈2023年員工持股計劃,員工持股計劃的股票來源為公司回購專用賬户回購的公司股票以及通過二級市場購買(包括但不限於大宗交易、集中競價交易、協議轉讓、融資融券)等法律法規許可的方式獲得的公司股票。本員工持股計劃擬籌集資金總額不超過2.5億元。
擬參加本次員工持股計劃的員工總人數不超過60人,本員工持股計劃的股票來源為公司回購專用賬户回購的公司股票以及通過二級市場購買(包括但不限於大宗交易、集中競價交易、協議轉讓、融資融券)等法律法規許可的方式獲得的公司股票。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.